Mobile Menu - OpenMobile Menu - Closed

E&C Announces Health Hearing on Neurodegenerative Diseases

Jul 22, 2021
Press Release

Energy and Commerce Committee Chairman Frank Pallone, Jr. (D-NJ) and Health Subcommittee Chairwoman Anna G. Eshoo (D-CA) announced today that the Health Subcommittee will hold a hearing on Thursday, July 29, at 11 a.m. (EDT). The hearing is entitled, “The Path Forward: Advancing Treatments and Cures for Neurodegenerative Diseases.”

“Today, millions of Americans and their families face the heartbreaking challenges of a neurodegenerative disease,” Pallone and Eshoo said. “While we have made progress in the quest to better understand neurodegenerative diseases, there is still much to do as we continue to support clinical research and development. As part of this ongoing effort, we will hear from officials at the Food and Drug Administration and the National Institutes of Health, as well as leading advocates, researchers, and industry representatives for an update on the search for new cures and treatments. We look forward to hearing how Congress can continue to support this critically important research and development work.”  

This will be a hybrid hearing that includes both in person and remote member attendance via Cisco Webex video conferencing. Members of the public may view the hearing via live webcast accessible on the Energy and Commerce Committee’s website. Please note the webcast will not be available until the hearing begins.

The Committee strongly recommends that members of the media view the proceedings remotely. The Capitol and House Office Buildings currently have restricted access. Seating in the Committee room for credentialed media is very limited. Media must RSVP to their respective press gallery no later than 5 p.m. on Wednesday, July 28.  

House Radio/TV Gallery:


House Periodical Gallery:


House Daily Press Gallery:


Photographer Gallery:


Information for this hearing, including the Committee Memorandum, witnesses, testimony, and a live webcast will be posted HERE as they become available.